journal article·2025-04Open access

PD-L1 siRNA incorporation into a cationic liposomal tumor mRNA vaccine enhances cytotoxic T cell activation and prevents immune evasion

Jingsheng Zhou, Yuanyuan Li, Xianghe Jiang, Zhongyuan Xin, Wenshang Liu, Xinyi Zhang, Yonghua Zhai, Zhuanzhuan Zhang, Te Shi, Minghao Xue, Mengya Zhang, Yan Wu, Yanhui Chu, Shimin Wang, Xin Jin, Weiping Zhu, Jie Gao

Abstract

T cells. Furthermore, cationic liposomes play dual roles as carriers crucial for preserving the integrity of nucleic acids for antigen translation and as inhibitors of autophagy-a process essential for both promoting antigen cross-presentation and revitalizing MHC-I expression on tumor cells, thereby increasing their immunogenicity. This cationic liposomal vaccine represents a promising strategy in cancer immunotherapy, launching a multidimensional offensive against tumor cells that enhances cytotoxic T lymphocyte (CTL) activation and prevents tumor immune evasion.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Immunotherapy and Immune Responses · RNA Interference and Gene Delivery · Cancer Immunotherapy and Biomarkers

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

References (79)

Show source-provided references
1. Development of effective tumor vaccine strategies based on immune response cascade reactions10.1002/adhm.202100299 ↗
2. Mechanisms of SARS-CoV-2 entry into cells10.1038/s41580-021-00418-x ↗
3. Structural biology of SARS-CoV-2 and implications for therapeutic development10.1038/s41579-021-00630-8 ↗
4. Lipid nanoparticle chemistry determines how nucleoside base modifications alter mRNA delivery10.1016/j.jconrel.2021.11.022 ↗
5. A single-dose mRNA vaccine provides a long-term protection for hACE2 transgenic mice from SARS-CoV-210.1038/s41467-021-21037-2 ↗
6. J. Liu, P. Budylowski, R. Samson, B.D. Griffin, G. Babuadze, B. Rathod, K. Colwill, J.A. Abioye, J.A. Schwartz, R. Law, L. Yip, S.K. Ahn, S. Chau, M. Naghibosadat, Y. Arita, Q. Hu, F.Y. Yue, A. Banerjee, W.R. Hardy, K. Mossman, S. Mubareka, R.A. Kozak, M.S. Pollanen, N. Martin Orozco, A.-C. Gingras, E.G. Marcusson, M.A. Ostrowski, Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B, Sci. Adv. 8 (n.d.) eabj9815. https://doi.org/10.1126/sciadv.abj9815.10.1126/sciadv.abj9815 ↗
7. The germinal centre B cell response to SARS-CoV-210.1038/s41577-021-00657-1 ↗
8. Advances in COVID-19 mRNA vaccine development10.1038/s41392-022-00950-y ↗
9. Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA10.1016/j.immuni.2005.06.008 ↗
10. Novel cap analogs for in vitro synthesis of mRNAs with high translational efficiency10.1261/rna.7380904 ↗
11. Cancer gene mutation frequencies for the U.S. population10.1038/s41467-021-26213-y ↗
12. The challenge and prospect of mRNA therapeutics landscape10.1016/j.biotechadv.2020.107534 ↗
13. The blockade of immune checkpoints in cancer immunotherapy10.1038/nrc3239 ↗
14. Recent advances in mRNA-LNP therapeutics: immunological and pharmacological aspects10.1186/s12951-022-01478-7 ↗
15. Self-assembled mRNA vaccines10.1016/j.addr.2020.12.014 ↗
16. Optimizing cardiac delivery of modified mRNA10.1016/j.ymthe.2017.03.016 ↗
17. Lipid nanoparticles for mRNA delivery10.1038/s41578-021-00358-0 ↗
18. Melittin-lipid nanoparticles target to lymph nodes and elicit a systemic anti-tumor immune response10.1038/s41467-020-14906-9 ↗
19. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients10.1038/sj.bjc.6602761 ↗
20. Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma10.1007/s00262-013-1453-3 ↗
22. How the T cell repertoire becomes peptide and MHC specific10.1016/j.cell.2005.05.013 ↗
23. MYC regulates the antitumor immune response through CD47 and PD-L110.1126/science.aac9935 ↗
24. Recent advances in overcoming barriers to cell-based delivery systems for cancer immunotherapy
25. Kinetics and nadir of responses to immune checkpoint blockade by anti-PD1 in patients with classical Hodgkin lymphoma10.1016/j.ejca.2017.12.015 ↗
26. EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma10.1016/j.biomaterials.2011.09.035 ↗
27. Inhibition of hepatocellular carcinoma growth using immunoliposomes for co-delivery of adriamycin and ribonucleotide reductase M2 siRNA10.1016/j.biomaterials.2013.08.088 ↗
28. Lipid nanoparticle (LNP) enables mRNA delivery for cancer therapy10.1002/adma.202303261 ↗
29. Autophagy promotes immune evasion of pancreatic cancer by degrading MHC-I10.1038/s41586-020-2229-5 ↗
30. Selectivity of mRNA degradation by autophagy in yeast10.1038/s41467-021-22574-6 ↗
31. Targeting RNA N6-methyladenosine to synergize with immune checkpoint therapy10.1186/s12943-023-01746-6 ↗
32. Autophagy modulation as a potential therapeutic target for diverse diseases10.1038/nrd3802 ↗
33. Targeting autophagy in cancer10.1038/nrc.2017.53 ↗
34. Cerebrospinal fluid efflux through dynamic paracellular pores on venules as a missing piece of the brain drainage system
35. EGFR-specific PEGylated immunoliposomes for active siRNA delivery in hepatocellular carcinoma10.1016/j.biomaterials.2011.09.035 ↗
36. An antibiotic-free platform for eliminating persistent Helicobacter pylori infection without disrupting gut microbiota10.1016/j.apsb.2024.03.014 ↗
37. X. Zhang, M. Zhang, H. Cui, T. Zhang, Z. Zhang, J. Li, J. Zhou, X. Jiang, C. Liu, J. Gao, Integrated Copper Nanomaterials-Decorated Microsphere Photothermal Platform for Comprehensive Melanoma Treatment, Small Structures n/a (n.d.) 2400028. https://doi.org/10.1002/sstr.202400028.10.1002/sstr.202400028 ↗
38. The protamine family of sperm nuclear proteins10.1186/gb-2007-8-9-227 ↗
39. Low molecular weight protamine (LMWP): a nontoxic protamine substitute and an effective cell-penetrating peptide10.1016/j.jconrel.2014.05.056 ↗
40. Nuclear matrix interactions at the human protamine domain: a working model of potentiation10.1074/jbc.M409415200 ↗
41. Protamine sulfate as an effective alternative to polybrene in retroviral-mediated gene-transfer: implications for human gene therapy10.1016/0166-0934(89)90132-8 ↗
42. Efficient colorectal cancer gene therapy with IL-15 mRNA nanoformulation10.1021/acs.molpharmaceut.0c00451 ↗
43. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells10.1021/mp060039w ↗
44. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA10.1038/mt.2008.51 ↗
45. Immunotherapy of tumor RNA-loaded lipid nanoparticles against hepatocellular carcinoma10.2147/IJN.S291421 ↗
46. Lipid nanoparticle formulations for enhanced Co-delivery of siRNA and mRNA10.1021/acs.nanolett.8b01101 ↗
47. Autophagy-modulating biomembrane nanostructures: a robust anticancer weapon by modulating the inner and outer cancer environment10.1016/j.jconrel.2023.12.032 ↗
48. Autophagy inhibition enhances PD-L1 expression in gastric cancer10.1186/s13046-019-1148-5 ↗
49. Factor of time in dendritic cell (DC) maturation: short-term activation of DCs significantly improves type 1 cytokine production and T cell responses10.1186/s12967-024-05368-4 ↗
50. Two-step maturation of immature DCs with proinflammatory cytokine cocktail and poly(I:C) enhances migratory and T cell stimulatory capacity10.1016/j.vaccine.2010.01.061 ↗
51. Monocyte-derived DC maturation strategies and related pathways: a transcriptional view10.1007/s00262-010-0954-6 ↗
52. Nucleic acids as antigens10.1016/S0065-2776(08)60523-4 ↗
53. Pathogen recognition by innate immunity and its signaling10.2183/pjab.85.143 ↗
54. Mechanism and medical implications of mammalian autophagy10.1038/s41580-018-0003-4 ↗
55. Engineering chameleon prodrug nanovesicles to increase antigen presentation and inhibit PD-L1 expression for circumventing immune resistance of cancer10.1002/adma.202102668 ↗
56. Dendritic nanomedicine with boronate bonds for augmented chemo-immunotherapy via synergistic modulation of tumor immune microenvironment
57. Nanopurpurin-based photodynamic therapy destructs extracellular matrix against intractable tumor metastasis10.1016/j.biomaterials.2018.04.045 ↗
58. Reprogramming the immunosuppressive tumor microenvironment through nanomedicine: an immunometabolism perspective10.1016/j.ebiom.2024.105301 ↗
59. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches10.1136/jitc-2021-003928 ↗
60. siRNA nanoparticle targeting PD-L1 activates tumor immunity and abrogates pancreatic cancer growth in humanized preclinical model10.3390/cells10102734 ↗
61. PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy10.1186/s12951-024-02700-4 ↗
62. ROS-sensitive PD-L1 siRNA cationic selenide nanogels for self-inhibition of autophagy and prevention of immune escape
63. Noncanonical splicing junctions between exons and transposable elements represent a source of immunogenic recurrent neo-antigens in patients with lung cancer10.1126/sciimmunol.abm6359 ↗
64. Microproteins encoded by noncanonical ORFs are a major source of tumor-specific antigens in a liver cancer patient meta-cohort10.1126/sciadv.adn3628 ↗
65. Enhancing CRISPR/Cas gene editing through modulating cellular mechanical properties for cancer therapy10.1038/s41565-022-01122-3 ↗
66. mRNA vaccine with antigen-specific checkpoint blockade induces an enhanced immune response against established melanoma10.1016/j.ymthe.2017.11.009 ↗
67. IL-20 antagonist suppresses PD-L1 expression and prolongs survival in pancreatic cancer models10.1038/s41467-020-18244-8 ↗
68. eEF2K promotes PD-L1 stabilization through inactivating GSK3β in melanoma10.1136/jitc-2021-004026 ↗
69. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single arm, phase 2 trial10.1016/S0140-6736(16)00561-4 ↗
70. PD-1 and its ligands in tolerance and immunity10.1146/annurev.immunol.26.021607.090331 ↗
71. The reversion of DNA methylation-induced miRNA silence via biomimetic nanoparticles-mediated gene delivery for efficient lung adenocarcinoma therapy10.1186/s12943-022-01651-4 ↗
72. A novel strategy inducing autophagic cell death in Burkitt's lymphoma cells with anti-CD19-targeted liposomal rapamycin10.1038/bcj.2014.2 ↗
73. Cationic liposomes promote antigen cross-presentation in dendritic cells by alkalizing the lysosomal pH and limiting the degradation of antigens10.2147/IJN.S125866 ↗
74. Tumor‐associated macrophage‐derived exosomal LINC01232 induces the immune escape in glioma by decreasing surface MHC‐I expression
75. Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer10.1038/nature22341 ↗
76. The relationship between autophagy and PD-L1 and their role in antitumor therapy10.3389/fimmu.2023.1093558 ↗
77. Oncogenic activation of the STAT3 pathway drives PD-L1 expression in natural killer/T-cell lymphoma10.1182/blood-2018-01-829424 ↗
78. Tuberculosis is associated with expansion of a motile, permissive and immunomodulatory CD16(+) monocyte population via the IL-10/STAT3 axis10.1038/cr.2015.123 ↗
79. Combination chemo-immunotherapy for pancreatic cancer using the immunogenic effects of an irinotecan silicasome nanocarrier plus anti-PD-1